Comparative study of adverse drug reactions associated with anifrolumab and belimumab for the treatment of systemic lupus erythematosus.
BackgroundAnifrolumab and belimumab are the two biologic agents currently approved for moderate-to-severe systemic lupus erythematosus (SLE), targeting distinct immunological pathways. While their efficacy has been established in randomized controlled trials, their comparative s…